Joseph Papin, MD, on Why EBITDA Expansion Alone Doesn’t Define Healthcare Deal Success
In many industries, EBITDA expansion is the clearest signal of a successful acquisition. In healthcare, it’s often the most misleading. For Joseph Papin, MD , the issue isn’t that EBITDA doesn’t matter—it’s that it rarely captures what actually determines long-term value in a healthcare organization. While financial performance may improve after a deal, this doesn’t always reflect stronger care delivery, better outcomes, or resilience. Healthcare doesn’t operate like a traditional services business. The underlying asset isn’t just revenue—it’s clinical performance. The Limits of Financial Metrics in Clinical Environments EBITDA expansion in healthcare is often driven by familiar levers: cost reduction, revenue cycle optimization, and payer mix improvement. While these are valid, they can create a false sense of progress when disconnected from clinical realities. Healthcare organizations are fundamentally complex systems. Staffing models, care pathways, referral networks, and patie...